TBA354
目录号 : GC11505
An antitubercular agent
Cas No.:1257426-19-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TBA354 is a new antitubercular agent [1].
TBA354 is a pyridine-containing biaryl compound against Mycobacterium tuberculosis. In 10 M. tuberculosis strains tested, the MIC range for TBA-354 was <0.02 to 0.36 μM. The MICs against S.aureus, E. coli, and C. albicans were >50 μM, suggesting TBA-354 is a narrow-spectrum agent. In Caco-2 cell bidirectional permeability assay, TBA-354 showed high permeability at 1 and 10 μM. TBA-354 was metabolically stable or moderately metabolized in incubations with liver microsomes. In HLM, TBA-354 (30 μM) showed weak inhibition of CYP3A4-catalyzed testosterone 6-hydroxylation by 40% [1].
In a low-dose aerosol infection model, TBA-354 dosed with 100 mg/kg daily for 5 of 7 days per week for 3 weeks showed significant bactericidal activity and reduced lung CFU by approximately 1 log10. In chronic murine TB, TBA-354 killed M. tuberculosis in a dose- and time-dependent way, and exhibited significant bactericidal activity. TBA-354 has high bioavailability and a long elimination half-life [1]. In murine models of tuberculosis, TBA-354 significantly increased the sterilizing activity of bedaquiline [2].
References:
[1]. Upton AM, Cho S, Yang TJ, et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2015, 59(1): 136-144.
[2]. Tasneen R, Williams K, Amoabeng O, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother, 59 :129-135.
| Cas No. | 1257426-19-9 | SDF | |
| 化学名 | (S)-2-nitro-6-((6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine | ||
| Canonical SMILES | FC(F)(OC1=CC=C(C2=NC=C(CO[C@@]3([H])CN4C=C(N(=O)=O)N=C4OC3)C=C2)C=C1)F | ||
| 分子式 | C19H15F3N4O5 | 分子量 | 436.34 |
| 溶解度 | ≥ 17.6mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2918 mL | 11.459 mL | 22.9179 mL |
| 5 mM | 0.4584 mL | 2.2918 mL | 4.5836 mL |
| 10 mM | 0.2292 mL | 1.1459 mL | 2.2918 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet